TrialCardiovascular diabetology2021

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.

Manige Konig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.